Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Benmelstobart first-line treatment for advanced NSCLC patients unsuitable for platinum doublet chemotherapy
ChiCTR2400085457Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and benmelstobart in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Started Jun 2024; status: recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400085457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085457.